Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J. Kuter, Janet L. Nichol, James B. Bussel et al.|The Lancet|2008Cited by 862
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and CarboplatinRonald S. Go, Alex A. Adjei|Journal of Clinical Oncology|1999Cited by 697
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneTina Green, Michael Møller, Ken H. Young et al.|Journal of Clinical Oncology|2012Cited by 682
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Youli Zu et al.|Blood|2013Cited by 677
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 YearsNarjust Duma, Alex A. Adjei, Jesus Vera Aguilera et al.|Journal of Oncology Practice|2017Cited by 447